Nampt and Naprt1: Novel polymorphisms and distribution of variants between normal tissues and tumor samples

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Duarte Pereira, Sara ^a   Silva, Sarah S ^a   Azevedo, Luísa ^a   Castro, Luísa ^b   Amorim, António ^a   Silva, Raquel M ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF AVEIRO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLYCOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; NICOTINATE PHOSPHORIBOSYLTRANSFERASE;

AMINO ACID SEQUENCE; BIOSYNTHESIS; DNA SEQUENCE; ENZYMOLOGY; GENE FREQUENCY; GENETICS; HUMAN; METABOLISM; NEOPLASM; NUCLEOTIDE SEQUENCE; PROMOTER REGION; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SEQUENCE; BASE SEQUENCE; CYTOKINES; GENE FREQUENCY; HUMANS; NAD; NEOPLASMS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PENTOSYLTRANSFERASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY;

EID: 84919623124     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06311     Document Type: Article

References (54)

1. Okumura, S., Sasaki, T., Minami, Y. & Ohsaki, Y. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation. J. Thorac. Oncol. 7, 49-56 (2012).
2. Magni, G. et al. Enzymology of NAD1 homeostasis inman. Cell. Mol. Life Sci. 61, 19-34 (2004).
3. Tempel, W. et al. Nicotinamide riboside kinase structures reveal new pathways to NAD1. PLoS Biol. 5, e263 (2007).
4. Hara, N. et al. Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J. Biol. Chem. 282, 24574-24582 (2007).
5. Chiarugi, A., Dolle, C., Felici, R. & Ziegler, M. The NAD metabolome-a key determinant of cancer cell biology. Nat. Rev. Cancer 12, 741-752 (2012).
6. Belenky, P., Bogan, K. L. & Brenner, C. NAD1 metabolism in health and disease. Trends Biochem. Sci. 32, 12-19 (2007).
7. Ocampo, A., Liu, J. & Barrientos, A. NAD1 salvage pathway proteins suppress proteotoxicity in yeast models of neurodegeneration by promoting the clearance of misfolded/oligomerized proteins. Hum. Mol. Genet. 22, 1699-1708 (2013).
8. Shackelford, R. et al. Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas. Anticancer Res. 33, 3047-3052 (2013).
9. Samal, B. et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 14, 1431-1437 (1994).
10. Fukuhara, A. et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307, 426-430 (2005).
11. Rongvaux, A. et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved inNAD biosynthesis.Eur. J. Immunol. 32, 3225-3234 (2002).
12. Dahl, T. B., Holm, S., Aukrust, P. & Halvorsen, B. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu. Rev. Nutr. 32, 229-243 (2012).
13. Olesen, U. H., Thougaard, A. V., Jensen, P. B. & Sehested, M. A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol. Cancer Ther. 9, 1609-1617 (2010).
14. Watson, M. et al. The small molecule GMX1778 is a potent inhibitor of NAD1 biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol. Cell. Biol. 29, 5872-5888 (2009).
15. Shames, D. S. et al. Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors. Clin. Cancer Res. 19, 6912-6923 (2013).
16. Bottcher, Y. et al. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. J. Clin. Endocrinol. Metab. 91, 2725-2731 (2006).
17. Jian, W. X. et al. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet. Med. 23, 967-973 (2006).
18. Reddy, P. S. et al. PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol. Ther. 7, 663-668 (2008).
19. Wang, L. S. et al. A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease. Mol. Biol. Rep. 38, 819-825 (2011).
20. Korner, A. et al. Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children. Metabolism 56, 772-777 (2007).
21. Bailey, S. D. et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 55, 2896-2902 (2006).
22. Johansson, L. M., Johansson, L. E. & Ridderstrale, M. The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects. Metabolism 57, 1558-1562 (2008).
23. Lasky-Su, J. et al. Genome-wide association scan of the time to onset of attention deficit hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 1355-1358 (2008).
24. Murphy, A. et al. Mapping of numerous disease-associated expression polymorphisms in primary peripheral blood CD41 lymphocytes. Hum. Mol. Genet. 19, 4745-4757 (2010).
25. Li, J. et al. Identification of high-quality cancer prognostic markers and metastasis network modules. Nat. Commun. 1, 34 (2010).
26. Supek, F., Minana, B., Valcarcel, J., Gabaldon, T. & Lehner, B. Synonymous mutations frequently act as driver mutations in human cancers. Cell 156, 1324-1335 (2014).
27. Chappie, J. S. et al. The structure of a eukaryotic nicotinic acid phosphoribosyltransferase reveals structural heterogeneity among type II PRTases. Structure 13, 1385-1396 (2005).
28. Ng, P. C. & Henikoff, S. Predicting deleterious amino acid substitutions. Genome Res. 11, 863-874 (2001).
29. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249 (2010).
30. Burgos, E. S., Ho, M. C., Almo, S. C. & Schramm, V. L. A phosphoenzyme mimic, overlapping catalytic sites and reaction coordinate motion for human NAMPT. Proc. Natl. Acad. Sci. USA 106, 13748-13753 (2009).
31. Saddi-Rosa, P., Oliveira, C. S., Giuffrida, F. M. & Reis, A. F. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol. Metab. Syndr. 2, 21 (2010).
32. Zhang, L. Q., Heruth, D. P. & Ye, S. Q. Nicotinamide Phosphoribosyltransferase in Human Diseases. J. Bioanal. Biomed. 3, 13-25 (2011).
33. Stastny, J. et al. Association of genetic variability in selected regions in visfatin (NAMPT) gene with anthropometric parameters and dietary composition in obese and non-obese Central-European population. Diabetes Metab. Syndr. 7, 166-171 (2013).
34. Sauna, Z. E.&Kimchi-Sarfaty, C. Understanding the contributionofsynonymous mutations to human disease. Nat. Rev. Genet. 12, 683-691 (2011).
35. Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46, 310-315 (2014).
36. Brunak, S., Engelbrecht, J. & Knudsen, S. Prediction of human mRNA donor and acceptor sites from the DNA sequence. J. Mol. Biol. 220, 49-65 (1991).
37. Olesen, U. H., Hastrup, N. & Sehested, M. Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas. APMIS 119, 296-303 (2011).
38. Cerna, D. et al. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53-and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner. J. Biol. Chem. 287, 22408-22417 (2012).
39. Hemani, G. et al. Detection and replication of epistasis influencing transcription in humans. Nature 508, 249-253 (2014).
40. Wang, T. et al. Structure of Nampt/PBEF/visfatin, a mammalian NAD1 biosynthetic enzyme. Nat. Struct. Mol. Biol. 13, 661-662 (2006).
41. Takahashi, R. et al. Structure and reaction mechanism of human nicotinamide phosphoribosyltransferase. J. Biochem. 147, 95-107 (2010).
42. Galassi, L. et al. Characterization of human nicotinate phosphoribosyltransferase: Kinetic studies, structure prediction and functional analysis by site-directed mutagenesis. Biochimie 94, 300-309 (2012).
43. Marchler-Bauer, A. et al. CDD: conserved domains and protein three-dimensional structure. Nucleic Acids Res. 41, D348-352 (2013).
44. Bogan, K. L. & Brenner, C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD1 precursor vitamins in human nutrition. Annu. Rev. Nutr. 28, 115-130 (2008).
45. Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792-1797 (2004).
46. Altschul, S. F. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25, 3389-3402 (1997).
47. Sali, A., Potterton, L., Yuan, F., van Vlijmen, H. & Karplus, M. Evaluation of comparative protein modeling by MODELLER. Proteins 23, 318-326 (1995).
48. Zhang, Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 9, 40 (2008).
49. Roy, A., Kucukural, A. & Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5, 725-738 (2010).
50. Sippl, M. J. Recognition of errors in three-dimensional structures of proteins. Proteins 17, 355-362 (1993).
51. Wiederstein, M. & Sippl, M. J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 35, W407-410 (2007).
52. Schrodinger, L. L. C. The PyMOL Molecular Graphics System, Version 1.3r1 (2010).
53. Flicek, P. et al. Ensembl 2014. Nucleic Acids Res. 42, D749-755 (2014).
54. 1000 Genomes Project Consortium. An integrated map of genetic variation from 1, 092 human genomes. Nature 491, 56-65 (2012).